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Evaluating ERK inhibitor sensitivity in HRAS-mutant head and neck squamous cell carcinoma 
 
Head and neck squamous cell carcinoma (HNSCC) is a significant public health problem and the 
prognosis is very poor. There are limited treatments. RAS is a membrane-associated GTP binding protein 
that is a well-established driver for cancer progression. One approach to target RAS is to inhibit the 
activity of its downstream effectors. Of many pathways that is downstream of RAS, a critical pathway in 
other cancers is the MAPK pathway. Activated RAS binds to RAF which in turns activates MEK1 and 
MEK2 protein kinases. Ultimately, the MEK1/2 protein kinases phosphorylate ERK1/2 which control 
critical cell processes. SCH772984 is an allosteric and ATP-competitive ERK inhibitor (ERKi). We 
hypothesized that ERKi would inhibit the growth of HRAS-mutant HNSCC cells such as UMSCC43. I 
first made sure that SCH772984 inhibited ERK1/2 signaling, by immunoblotting for loss of activity of 
ERK and its substrates. I then evaluated the effect of ERK inhibition upon both anchorage-dependent and 
independent cell growth. In addition, I analyzed the cell cycle distribution upon treatment with ERK 
inhibitor using flow cytometry. The results showed that the doses I used did inhibit the growth in 
anchorage-dependent and –independent conditions. This study was limited to one cell line. Further studies 
in additional cell lines and at lower doses of ERK inhibitor are needed to evaluate the consequences of 
inhibition of ERK activity in HNSCC. 
 
